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The induction of type I interferons by most RNA viruses is initiated by virus-derived double-stranded (ds)RNA. However,
retro- and DNA-viruses, which do not synthesize dsRNA, must rely on different mechanisms of induction. For human
immunodeficiency virus type 1 (HIV-1), recombinant glycoproteins 120 or 160 suffice to induce interferon (IFN)-a in
blood-derived lymphocytes [H. Ankel, M. R. Capobianchi, C. Castilletti, and F. Dianzani (1994). Virology 205, 34–43]. Here we
show that for herpes simplex virus type 1 (HSV-1) recombinant glycoprotein, gD is the major inducer, whereas gB, gC, gE,
gG, gI, and the complex of gH and gL are poor inducers. The recombinant extramembrane fragment of gD was sufficient to
induce IFN-a levels comparable to that of intact virus. Like with HIV-1, induction was inhibited by a monoclonal antibody that
recognizes cerebrosides and sulfatides. Furthermore, monoclonal antibodies specific for the chemokine receptors CCR3 and
CXCR4 also blocked induction. We conclude that HSV-1 induces IFN-a by interaction of its glycoprotein gD with appropriate
receptors on IFN-producing cells. Based on the known receptor roles of galactosyl cerebrosides and chemokine receptors
in HIV infection, such structures on IFN-producing cells could also participate in the induction of IFN-a by HSV-1. © 1998
Academic Press
INTRODUCTION
Interferons (IFNs) are important mediators of the early
host defense against many viral infections, and most
viruses induce IFNs in infected individuals and in cells in
culture. IFN-producing cells are contained in freshly iso-
lated PBMCs from health donors (Fitzgerald-Bocarsly,
1993). When challenged with viruses such as herpes
simplex virus (HSV) or human immunodeficiency virus
(HIV), these cells produce IFNs of the a type (IFN-a),
representing a family of homologous polypeptides (Fer-
bas et al., 1994; Fitzgerald-Bocarsly, 1993; Svensson et
al., 1996). Analogous results are seen using UV-inacti-
vated virus as inducer, indicating that replication is not
required for IFN-a induction. In fact, virus-infected cells
that express viral envelope components on their surface
are excellent inducers, even when cross-linked by glu-
taraldehyde, which renders endogenous virus noninfec-
tious (Ankel et al., 1996; Capobianchi, 1996; Lebon, 1985).
Previous studies have shown that antibodies against the
major envelope glycoprotein of HIV, gp120, blocked
IFN-a induction in PBMCs not only by the virus but also
by cross-linked HIV-1-infected cells. Furthermore, the
pretreatment of PBMCs with antibodies to the CD4 re-
ceptor of HIV-1 suppressed induction of IFN-a by the
virus as well as by HIV-1-infected cells (Francis and
Meltzer, 1993). A direct role of gp120 in induction was
shown by the fact that a recombinant preparation of the
glycoprotein induces IFN-a in the absence of any other
viral component (Ankel et al., 1994; Capobianchi et al.,
1992). Thus for the retrovirus HIV-1, these data provide
evidence for an induction mechanism that is initiated by
interaction of its viral envelope glycoprotein with the cell
surface antigen CD4. Furthermore, antagonistic effects
of exogenous sulfatides or cerebroside/sulfatide specific
antibodies suggest an additional role for these glycolip-
ids during induction (Ankel et al., 1996). The involvement
of other peptide sequences of gp120 in addition to its
CD4 binding site is suggested by inhibitory effects of
monoclonal antibodies to overlapping epitopes on its V3
loop (Ankel et al., 1994). Indeed, this domain is impli-
cated in interaction of HIV-1 with glycolipids and with
chemokine receptors, recently discovered coreceptors of
HIV infection (Alizon, 1997; Baggiolini, 1998; Cook et al.,
1994; D’Souza and Harden, 1996; Wu et al., 1997). An
interferonogenic glycoprotein has also been described
for transmissible gastroenteritis virus (TGEV) (Laude et
al., 1992).
In this communication, we investigated whether the
enveloped DNA virus HSV-1 relies on a similar mecha-
nism of IFN-a induction. HSV-1 expresses $11 glyco-
proteins, of which 8 are known constituents of the viral
envelope. Of the latter group, glycoproteins gB, gC, and
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gD and a heterodimeric complex of gH and gL are
directly involved in virus attachment and/or entry into
susceptible cells (Cai et al., 1988; Forrester et al., 1992;
Herold et al., 1991; Hutchinson et al., 1992; Johnson and
Ligas, 1988; Peng et al., 1998; Spear, 1993). Although
glycoproteins gE, gG, and gI are also constituents of the
viral envelope, their role in HSV-1 infection remains un-
defined (Spear, 1993). However, they appear to have
other important functions in that they have been main-
tained throughout evolution and structural homologs are
present on most other members of the alphaherpesvirus
family. Glycoproteins gB and gC are known to bind to
heparan sulfate side chains on membrane proteogly-
cans, and both are important in the initial phase of virus
attachment (Kuhn et al., 1990; Trybala et al., 1993). In
contrast, limited numbers of specific cell membrane re-
ceptors exist for gD, as judged from binding studies
using radiolabeled recombinant gD constructs (Johnson
et al., 1990). Recently a human cell membrane compo-
nent related to the TNF receptor family was cloned,
which specifically bound recombinant gD. When HSV-1-
resistant Chinese hamster ovary cells were transfected
to express this component, they became sensitive to
infection, suggesting that it can serve as a receptor in
HSV-1 infection by attaching to gD (Montgomery et al.,
1996; Whitbeck et al., 1997).
Previous studies of the mechanism of IFN-a induction
in human PBMCs by HSV-1-infected Vero cells indicated
a possible role for glycoprotein gD. When the inducer
cells were pretreated with monoclonal antibodies
against gB, gC, or gD, only the gD-specific one resulted
in pronounced inhibition of induction, suggesting a direct
function of this glycoprotein in the induction process
(Lebon, 1985). Progress in cloning and expression of
individual HSV glycoproteins has provided new tools to
more clearly define the role of individual envelope gly-
coproteins in the induction of IFN-a (Ghiasi et al., 1991,
1992a, 1992b, 1992c, 1992d, 1992e, 1994; Westra et al.,
1997). Specifically it allows one to ask whether induction
is triggered by one or several envelope glycoproteins, or
whether other viral components are also necessary. As
described in this communication, we used Spodoptera
frugiperda insect cells (Sf9) expressing individual HSV-1
glycoproteins on their surface, as potential IFN-a induc-
ers in human PBMCs (Ghiasi et al., 1994). In comparing
such glycoprotein vehicles carrying six of the known
surface membrane glycoproteins individually, we show
that among them gD is the most potent IFN-a inducer.
Glycoproteins gB, gC, gE, gG, and gI, when used under
identical conditions, showed little induction. A possible
exclusive role of gD in induction was confirmed by using
a recombinant-soluble version of the extramembranous
portion of the polypeptide. This preparation induced
IFN-a to levels comparable to those observed with the
intact virus or with gD-expressing Sf9 cells. A soluble
recombinant gH–gL complex, on the other hand, was
inactive, supporting the conclusion that gD is the major
IFN-a-inducing component of the viral envelope. Surface
components of target cells involved in IFN-a induction
were studied by the use of monoclonal antibodies to
defined cell membrane antigens. Based on these stud-
ies, we propose a scenario of IFN-a induction that is
similar for both HSV and HIV and involves galactosyl
cerebrosides/sulfatides and the chemokine receptors
CCR3 and CXCR4.
RESULTS
IFN-a induction by HSV-derived glycoproteins
expressed by insect Sf9 cells
Like intact or UV-inactivated virus, HSV-infected mam-
malian cells, cross-linked with glutaraldehyde, effectively
induce IFN-a in PBMCs (Lebon, 1985). To investigate
whether IFN-a induction by HSV-1 is dependent on a
specific glycoprotein of the virus, we used insect Sf9
cells that presented individual HSV-1 membrane glyco-
proteins gB, gC, gD, gE, gG, and gI on their surface. Sf9
cells infected with baculovirus expressing HSV-2-derived
glycoprotein D (Sf9-gD2) were also included for compar-
ison. As indicated in Table 1 the various Sf9 cell prepa-
rations showed strong fluorescence with their cognate
monoclonal antibodies (mAbs) but were negative for the
others. They also fluoresced with human and rabbit anti-
HSV-1 antisera, as did gI-expressing cells for which no
specific antibody was available to us. Surface expres-
sion of specific glycoproteins on Sf9 cells was confirmed
by immunofluorescence of nonpermeabilized cells and
corresponded to previously published results (Ghiasi et
al., 1994). As expected, uninfected or wild-type virus-
infected control cells lacked immunofluorescence in re-
sponse to the HSV-specific antibodies.
Freshly isolated human PBMCs were incubated over-
night with glutaraldehyde-fixed Sf9 cells presenting indi-
vidual HSV-derived glycoproteins, at an Sf9/PBMC cellu-
lar ratio of 1:30.
Levels of human IFN-a were then determined in the
incubation supernatants. Table 2 compares yields of
IFN-a that were obtained in repeated experiments using
PBMCs from different donors. As seen in the Table,
IFN-a induction was strongest with Sf9 cells expressing
glycoprotein gD. Sf9 cells containing gD from the KOS
strain of HSV-1 yielded the same amounts of IFN-a as
the McIntyre strain-derived construct (not shown). Also,
Sf9-gD2 cells containing HSV-2-derived glycoprotein
were equally potent IFN-a inducers. Clearly, Sf9 cells
expressing gB, gC, gE, gG, or gI induced only small
amounts of antiviral activity. Even less was seen with
wild-type baculovirus-infected cells. The Table gives
mean values and standard deviations of IFN-a levels,
which demonstrate the variability of the IFN response in
different donors. Thus using mixtures of Sf9-gD cells with
PBMC preparations from 16 different donors, levels var-
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ied beween 400 and 3200 IU/ml. In the associated col-
umn, yields of IFN-a obtained with different glycoprotein
constructs are expressed as percent of those obtained
with Sf9-gD cells in parallel experiments using the same
PBMC preparations and represent ;#5%.
Figure 1 compares representative experiments of the
dose response of IFN-a induction by HSV-1 (top) with
that by Sf9-gD (bottom). Half-maximal induction occurred
at an Sf9-gD/PBMC ratio of ;1:100 and at a virus/PBMC
ratio of ;1:2000, indicating greater inducing efficiency of
the viral particles. That the antiviral activity produced in
TABLE 1
Immunofluorescence with Indicated Antibodies
SF9 Cells
expressing
% Fluorescent cellsa
HSV-1 b
mAB to
baculo gp67
mABs to HSV-1 glycoproteins
H R gB gC gD gE gG
gB (1c) 31 21 31 41 — — — —
gC (1) 31 31 31 — 41 — — —
gD1 (5) 31 31 31 — — 41 — —
gD2 (3) 31 31 21 — — 31 — —
gE (1) 21 31 41 — — — 31 —
gG (4) 21 21 31 — — — — 31
gI (2) 21 31 31 — — — — —
WTd (3) — — 21 — — — — —
Uninfected — — — — — — — —
a t41: 75–100%; 31: 50–75%; 21: 25–50%; —: background fluorescence.
b H, human antiserum; R, rabbit antiserum.
c Number of SF9-cell isolates for which complete antibody panel was done.
d SF9 cells infected with wild-type baculovirus.
TABLE 2
IFN-a Induction by SF9 Cells Expressing Individual HSV
Glycoproteins
Glycoproteins
expressed
Number of
donors
IFN-a
IU/mla
% of gD
inducedb
gB 6 84 6 41 6 6
gC 3 53 6 49 5 6 1
gD1 16 1625 6 934 100
gD2 4 1879 6 1033 91 6 44
gE 4 47 6 49 5 6 2
gG 3 24 6 20 2 6 1
gI 3 52 6 7 3 6 3
Control Wtc
Infected cells 11 6 6 19 1 6 2
Control
Uninfected cells 4 ,1 ,1
a Mean 6 standard deviation of IFN-a induced.
b Mean 6 standard deviation relative to SF9-gD induced amount in
the same PBMC isolate.
c Wild-type baculovirus.
FIG. 1. Induction of IFN-a by HSV-1 or Sf9 cells expressing gD
(Sf9-gD). PBMCs were induced with indicated amounts of HSV-1 (top)
or Sf9-gD (bottom), and antiviral titers in culture supernatants were
determined as described under Materials and Methods. Representa-
tive examples from a total of 5 (top) and 13 (bottom) experiments are
shown.
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response to Sf9-gD is of the a type was concluded from
its antiviral effect on MDBK cells, which respond poorly
to human IFNs b or g (Gresser et al., 1974). This was
confirmed by complete (.99%) neutralization by IFN-a-
specific antiserum. The same neutralization was seen
with Sf9-gD2-and HSV-1-induced antiviral activities.
Effects of antibodies to HSV glycoproteins
We further confirmed the role of gD in the induction of
IFN-a by comparing the effects of antisera and monoclo-
nal antibodies on inducing activities of intact HSV-1 and
Sf9-gD cells. As shown in Fig. 2 (left), decomplemented
serum from an HSV-1-positive patient progressively sup-
pressed induction by intact HSV-1, whereas serum from
an HSV-1 negative control did not. The patient serum
also blocked induction by Sf9-gD. Similar results were
seen with two additional HSV-1 positive sera (not
shown). Furthermore, the virus-neutralizing gD-specific
mAb LP2 blocked IFN-a induction of both the virus and
the gD-expressing Sf9 cells in a similar manner (Fig. 2,
right). LP2, which neutralizes both HSV-1 and HSV-2, also
blocked IFN-a induction by gD2-expressing Sf9 cells (not
shown). Another neutralizing gD-specific mAb (4S) that
blocked induction by HSV-1-infected Vero cells (Lebon,
1985) was also inhibitory to induction by HSV-1 and by
Sf9-gD (not shown). On the other hand, the non-neutral-
izing mAbs H2B4B1, B1C1B4, E5G3G9, and B1E6A5 rec-
ognizing gB, gC, gD, and gE, respectively, had no effects
on IFN-a induction by HSV-1. All antisera and mAbs
tested in these experiments had no effects on IFN-a
induction by vesicular stomatitis virus (VSV) or Sendai
virus when used under comparable conditions.
Effects of antibodies to cell membrane constituents
In previous work, HIV-1-dependent IFN-a induction
was found to be blocked by preincubation of PBMCs with
an mAb that recognizes the galactosyl-sphingosine moi-
eties of galactosyl cerebrosides and sulfatides (mAb
GalC; Ankel et al., 1996). We tested the effects of the
same antibody on IFN induction by HSV-1. As can be
seen in Fig. 3, similar inhibitory effects on IFN-a induc-
tion occurred with either intact HSV-1 (left) or Sf9-gD
cells (right) as inducers. IFN-a induction by intact VSV
was not influenced by the presence of mAb GalC, indi-
cating that the results are not due to nonspecific and/or
toxic effects. The same lack of inhibition by mAb GalC
was seen when a poliovirus–immunoglobulin complex
was used as inducer. In this case, induction occurs via
interaction with the CD32 receptor on the responder
cells (P. Lebon, unpublished observation).
Chemokines represent an extended family of che-
FIG. 3. Inhibition of HSV-1- or Sf9-gD-dependent IFN-a induction by
galactosyl cerebroside/sulfatide-specific mAb GalC. PBMCs were pre-
incubated with indicated amounts of the mAb, followed by the addition
of HSV-1 (104 PFU/ml; left) or Sf9-gD (105 cells/ml; right). Control IFN-a
levels were 100 IU/ml (left) and 1500 IU/ml (right). Lack of inhibition of
VSV-dependent induction is indicated by the square. Representative
examples of four (left) and three (right) experiments are shown.
FIG. 2. Inhibition of HSV-1 or Sf9-gD dependent IFN-a induction by
anti-HSV-1 human serum or mAb anti-gD. HSV-1 (top) or Sf9-gD (bot-
tom) was preincubated either with indicated amounts of human HSV-
1-positive serum (left) or gD-specific mAb LP2 (right). HSV-1 concen-
trations were 104 PFU/ml (left) and 105 PFU/ml (right). Sf9-gD concen-
trations were 2 3 104 cells/ml (left) and 5 3 104 cells/ml (right). PBMCs
were then added, and incubations continued for 18 h, followed by
determinations of antiviral titers as described under Materials and
Methods. Control titers were 500 IU/ml (top left), 4000 IU/ml (top right),
100 IU/ml (bottom left), and 4000 IU/ml (bottom right). Squares repre-
sent control experiments using VSV (top) or Sendai virus (bottom) as
inducers in the presence of indicated amounts of antibody. The triangle
shows lack of inhibition by an HSV-1-negative control serum. Repre-
sentative examples of a total of 7 (top left), 10 (top right), 4 (bottom left),
and 3 (bottom right) experiments are shown.
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moattractants that direct blood leukocytes to sites of
infection and inflammation. They also act as regulatory
molecules of lymphocyte migration and adhesion and
have other regulatory functions related to the develop-
ment of leukocytes and lymphoid tissue (Baggliolini,
1998). Recent work has established that several of the
known chemokine receptors, including CCR3, CCR5, and
CXCR4, can also serve as coreceptors for infection by
HIV-1 and related retroviruses (Alizon, 1997; D’Souza and
Harden, 1996). To investigate the role of these receptors
in HSV-1-dependent IFN-a induction, we studied the ef-
fects of chemokine-specific mAbs that block infection by
HIV-1. As shown in Fig. 4, pretreatment of PBMC with
either mAb 7B11 (CCR3 specific) or mAb 12G5 (CXCR4
specific) suppressed IFN-a induction by either the intact
virus (top) or Sf9-gD cells (bottom). However, with both
antibodies, much higher concentrations were required
for inhibition of the viral inducer compared with the
Sf9-gD cell-associated one. This could be due to tighter
binding of the virus to both receptors compared with
gD-expressing cells, requiring higher antibody concen-
trations to compete off the virus. Both antibodies were
without effects on IFN induction by VSV, suggesting dif-
ferent modes of induction and excluding cytotoxic effects
of the antibody preparations.
IFN-a induction by soluble recombinant gD1
To further substantiate that gD is, indeed, capable of
inducing IFN-a, it was desirable to show induction by a
soluble version of the glycoprotein in the absence of
other viral components. We used a recombinant trun-
cated form of gD representing its extramembraneous
portion, which was isolated from the culture supernatant
of Spodoptera frugiperda cell cultures after infection with
a baculovirus construct expressing the N-terminal 315
residues of the mature glycoprotein (gDt). As shown in
Fig. 5, IFN-a was dose-dependently induced, and half-
maximal induction was estimated to occur at a glyco-
protein concentration of ;0.3 mM. Maximal amounts of
antiviral activity were similar to those obtained with in-
tact virus or Sf9-gD cells and occurred at inducer con-
centrations from ;0.8 mM on. Because the heterodimer
complex of gH and gL is necessary for cell penetration of
HSV-1, we also investigated the IFN-a-inducing potential
of a recombinant soluble version of this complex that
was truncated at the amino end of the transmembrane
sequence of gH (gHt/gL; Westra et al., 1997). As indi-
cated in Fig. 5, gHt/gL did not induce an antiviral re-
sponse at doses close to those for half-maximal induc-
tion by gDt. To further corroborate this result, we used a
gH/gL-specific rabbit antiserum (5R127) that had been
previously found to block virus entry at a 1000-fold dilu-
tion (Peng et al., 1998). In experiments essentially iden-
tical to those described for Fig. 2, we observed no inhi-
bition of HSV-1-dependent induction up to a 1:50 dilution
FIG. 5. IFN-a induction by soluble recombinant glycoprotein gDt.
PBMCs were incubated with indicated amounts of gDt, and antiviral
titers were determined essentially as described under Materials and
Methods. The triangle shows lack of IFN-a induction by a soluble
recombinant gHt/gL heterodimer at the indicated micromolar concen-
tration. A representative example of five experiments is shown.
FIG. 4. Effects of mAbs specific for chemokine receptors CCR3 or
CXCR4 on IFN-a induction by HSV-1 or Sf9-gD. PBMC were preincu-
bated with indicated amounts of mAbs 7B11 (CCR3 specific) or 12G5
(CXCR4 specific) before the addition of the inducers HSV-1 (104 PFU/ml;
top) or Sf9-gD (2 3 105 cells/ml; bottom). Control IFN-a titers were 600
IU/ml (top) and 2700 IU/ml (bottom). Squares indicate lack of inhibition
when VSV was used as the inducer. Representative examples of two
(top left), five (top right), two (bottom left), and five (bottom right)
experiments are shown.
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of the antiserum (not shown). This result also suggests
that the gH–gL complex plays no role in IFN-a induction.
The gDt-induced antiviral activity is of the a type based
on its activity in MDBK cells and on its inhibition with
IFN-a-specific antiserum. As shown in Fig. 6, induction
by gDt was inhibited by a human anti-HSV-1 antiserum
and by the gD-specific mAb LP2, excluding that induction
is due to non-HSV-1 or non-gD contaminants present in
the preparation. Higher mAb concentrations were nec-
essary to block gDt-dependent induction compared with
induction by intact virus. This is expected in that actual
amounts of gD that cause induction are much higher for
soluble gD than for the virus-bound version.
We also assessed the effects of the cell membrane-
specific mAbs that blocked induction by HSV-1- or cell-
bound inducer on induction by soluble gDt. The results in
Fig. 7 show the inhibitory effects of mAb GalC for the
soluble inducer, which are similar to the effects seen for
intact HSV-1 and Sf9-gD (see Fig. 3). Thus the same
glycolipid involvement in IFN-a induction is suggested
for all three inducers. In addition, the same CCR3- and
CXCR4-specific mAbs that blocked induction by HSV-1
and Sf9-gD also blocked induction by gDt (Fig. 8). As
seen in the Figure, much lower concentrations of both
antibodies were required to block gDt-dependent induc-
tion compared with induction by the intact virus, compa-
rable to the results seen with gD-expressing Sf9 cells
(see Fig. 4). As suggested above, this could be due to
tighter binding of the virus to each of both receptors
relative to the soluble form of gD.
DISCUSSION
We studied a possible role of HSV-derived envelope
glycoproteins in the induction of IFN-a in human PBMCs.
In one approach, we incubated PBMCs with insect Sf9
cells that individually expressed six of these glycopro-
teins in the absence of any other herpes virus- or mam-
malian cell-derived antigens (Ghiasi et al., 1994). In a
second approach, we tested soluble recombinant glyco-
proteins lacking transmembrane and intracellular do-
mains. Because the infection-promoting form of gH and
gL is a heterodimeric complex of both glycoproteins, we
used a recombinant version in which full-length gL is
complexed with truncated gH component (gHt–gL). Such
a preparation, when injected into rabbits, produced an-
tibodies that blocked HSV-1 infection, thus appearing to
have a conformation close to its functional form (Peng et
al., 1998). However, we did not observe induction of
IFN-a with the heterodimer construct that we used. In
FIG. 6. Inhibition of gDt-dependent IFN-a induction by anti-HSV-1
serum or mAb anti-gD. Glycoprotein (0.3 mM) was preincubated with
indicated amounts of human HSV-1-positive serum (left) or gD-specific
mAb LP2 (right). PBMCs were then added, and antiviral titers were
determined after an additional 18 h of incubation. Control titers of IFN-a
were 250 IU/ml (left) and 100 IU/ml (right). The squares represent
control experiments using VSV as inducer. In each case, a represen-
tative example of a total of four experiments is shown.
FIG. 7. Effects of the galactosyl cerebroside/sulfatide-specific mAb
GalC on IFN-a induction by gDt. The experiment was carried out
essentially as described under Materials and Methods, using 0.3 mM
gDt as inducer. Control titer of IFN-a was 300 IU/ml. The square shows
lack of inhibition with VSV as the inducer. A representative example of
a total of three experiments is shown.
FIG. 8. Effects of chemokine receptor-specific mAbs on IFN-a induc-
tion by gDt. Experiments were carried out essentially as described
under Materials and Methods, using 0.3 mM gDt as inducer. Control
levels of IFN-a were 800 IU/ml (left) and 500 IU/ml (right). Squares
represent control experiments using VSV as inducer. Representative
examples of four (left) and five (right) experiments are shown.
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addition, the truncated construct of gD was used to
confirm the role of this glycoprotein in IFN-a induction in
the absence of other viral components. A similar gD
construct was previously shown to block HSV infection
and to specifically bind to a limited number of cell re-
ceptors, also suggesting that it retained its natural con-
formation (Johnson et al., 1990). Based on our results, we
conclude that glycoprotein gD is the main membrane
component that is responsible for IFN-a induction by
HSV-1. Furthermore, the results with Sf9 cells expressing
HSV-2-derived gD (gD2) suggest a similar role for this
glycoprotein in IFN induction by HSV-2.
One half of maximal induction by gDt occurred at an
inducer concentration of ;0.3 mM. This value is close to
a dissociation constant of 0.26 mM for the soluble gDt–
cell receptor complex (Johnson et al., 1990). This result
suggests that 50% of maximal induction occurs close to
a receptor occupancy of 50% and thus favors a receptor-
mediated phenomenon involving intact gDt without prior
processing. However, reactive concentrations of gDt are
much higher than those of the virus-bound inducer; thus
different induction mechanisms for soluble and particle-
bound gD cannot be excluded. In fact, prior attachment
of intact virus to responder cells via gB or gC, or both,
might allow for tighter interaction of virus-bound gD with
responder cell receptors, despite their relatively low af-
finity for soluble gD. Similar observations were made in
studies of IFN-a induction in PBMCs by HIV-1-derived
soluble gp120. The gp120 concentration yielding half-
maximal IFN-a induction was also close to the dissoci-
ation constant of the soluble glycoprotein cell–receptor
complex and thus compatible with half-saturation of re-
ceptor occupancy. Again it was much higher than that of
virus-bound glycoprotein that yielded the same response
(Ankel et al., 1994).
Similarities between induction by HIV-1 and HSV-1
extend further, as in both cases IFN-a induction is inhib-
ited by an mAb that specifically recognizes galactosyl-
sphingosinyl moieties of galactosyl cerebrosides and
sulfatides. These glycolipids are prominent membrane
components and might be necessary participants in
membrane fusion of both viruses via their respective
glycoproteins. Alternatively they might be active partici-
pants in transmembrane signaling via their lipid compo-
nents ceramide or sphingosine, as discussed previously
(Ankel et al., 1996). In fact, a regulatory role of ceramides
in the function of dendritic cells has been proposed
(Sallusto et al., 1996).
The antagonistic effects of anti-chemokine receptor
antibodies to IFN-a induction by HSV-1 and its glyco-
protein gD were unexpected. A possible functon of che-
mokine receptors in IFN-a induction could be based on
a role of chemoattraction of IFN-a-producing cells and
antigen-presenting cells (Baggliolini, 1998; Bancherau
and Steinman, 1998). In fact, using immunocytochemistry
to visualize intracellular IFN-a, clusters of IFN-producing
cells with nonproducing cells have been observed (Feld-
man and Fitzgerald-Bocarsly, 1990; Fitzgerald-Bocarsly,
1993).
On the other hand, chemokine receptors play an impor-
tant coreceptor role in HIV infection, although such a role
for HSV-1 has not previously been described (Alizon, 1997;
D’Souza and Harden, 1996). The mAbs that we found to be
inhibitory to IFN-a induction block either the CXCR4 or the
CCR3 receptors. They are known antagonists of infection
by certain laboratory-adapted or primary isolates of HIV-1
(Endres et al., 1996; Heath et al., 1997). Our results suggest
that the same receptors on IFN-producing cells might also
interact with the gD component of HSV. In fact, enriched
IFN-producing cells resemble dendritic cells, which are
known to express both CCR3 and CXCR4 receptors
(Banchereau and Steinman, 1998; Dittmar et al., 1997;
Granelli-Piperno, 1996). Chemokine receptors are mem-
brane components that meander in and out of the cellular
membrane. They contain seven membrane-spanning do-
mains and display four peptide sequences on the exterior
side of the cell. Theoretically an infecting virus such as HIV
could attach to any one of the exterior segments of such a
structure. The CXCR4-specific mAb 12G5 attaches to the
third extracellular domain of the receptor (Alizon, 1997;
Brelot et al., 1997). Apparently this loop is also involved in
the interaction with gD because gD-dependent IFN-a in-
duction is blocked by 12G5. The epitope that is recognized
by the CCR-3-specific antibody 7B11 has not as yet been
characterized. However, because 7B11 also blocks induc-
tion, the latter epitope likewise appears to interact with gD.
Our findings provide another example for the phenom-
enon that a virus-encoded glycoprotein that is essential
for infection can also trigger the induction of an antiviral
response that can limit its spread. The same phenome-
non was described earlier for HIV-1, which is unrelated to
the DNA virus studied here but codes for the same type
of bifunctional glycoprotein (Ankel et al., 1994, 1996;
Capobianchi et al., 1992). Like gD of HSV, gp120 of HIV-1
is essential for infection, yet it also induces antiviral
activity via IFN-a. Probably such dual activity has evolved
to allow for the coexistence of both the infected host and
the infectious agent. In addition, our results suggest that
interaction of HSV-1 with immune cells other than those
producing IFN could cause agonistic or antagonistic
actions on chemokine function, which could play a role in
the pathobiology in the virus. Thus consequences for the
infected host beyond cytopathic action of the virus, such
as stimulatory or inhibitory effects of gD on the immune
system via cytokine or chemokine dysfunction, should be
considered.
MATERIALS AND METHODS
Cells and virus
Sf9 cells (CRL 1711) were from ECACC (Salisbury, UK).
They were grown in TC-100 medium (Aldrich, France)
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containing 10% fetal bovine serum (FBS) at 28°C. Wild-
type Autographa californica nuclear polyhydrosis virus
(baculovirus) was obtained from Novagen (Abingdon,
UK). All HSV-derived glycoproteins referred to in the text
are those of HSV-1 except gD2, which is the HSV-2-
derived species. Baculovirus constructs expressing indi-
vidual HSV-1( KOS) glycoproteins gB, gC, gD, gE, gG, and
gI were generously supplied by Dr. Homayon Ghiasi (Los
Angeles, CA) (Ghiasi et al., 1991, 1992a, 1992b, 1992c,
1992d, 1992e, 1994). Baculovirus constructs expressing
HSV-1 (McIntyre)-derived gD1 and HSV-2 (strain 333)-
derived gD2 were produced essentially as described for
the other glycoproteins (Damhof, 1995; Ghiasi et al.,
1994). Titers of baculovirus stocks ranged from 5 3 107 to
2 3 108/ml. Monolayers of Sf9 cells were infected with
baculovirus suspensions at an m.o.i. of ;10–20 and
incubated for 48–72 h at 28°C, when most of the cells no
longer adhered to the culture flasks. Cells were har-
vested and washed several times with PBS and then
suspended in PBS containing 0.1% glutaraldehyde for 1 h
at 4°C. Cells were washed again with PBS and sus-
pended in 0.3% glycine containing PBS to inactivate all
traces of glutaraldehyde. After overnight storage at
0–4°C, cells were washed again with PBS and then
suspended to 106/ml in RPMI–10% FBS and stored at
0°C. Expression of individual glycoproteins was moni-
tored by immunofluorescence using antisera or individ-
ual mAbs (see below). Of the transfected Sf9 cells that
were used in the IFN-a induction assays, routinely 50–
90% expressed the HSV-derived glycoprotein under
study.
Stocks of HSV-1 (Shealy) were prepared from super-
natants of infected Vero cells cultured in RPMI–2% FBS
72 h p.i. at an m.o.i. of 0.1 and had a titer of 106 to 107
PFU/ml. Stocks of VSV were likewise obtained from
RPMI-cultured Vero cell supernatants 48–72 h p.i. at an
m.o.i. of ;0.01. Their titer was 107 PFU/ml. Stocks of
Sendai virus (E 72) were obtained after infection of em-
bryonated chicken eggs and had a titer of 108 infectious
doses/ml. In control induction mixtures, both viruses
were used at dilutions of 10-3. Inactivated poliovirus vac-
cine was obtained from Pasteur (Merieux, Paris). One
volume of a 1:1 vaccine dilution in RPMI–10% FBS was
mixed with 1 volume of a 5% g-globulin solution (LFB,
Paris) and used as controls in some of the IFN-a induc-
tion assays (P. Lebon, unpublished observations). Pe-
ripheral blood mononuclear cells from healthy donors
negative for HIV, HTLV-1, hepatitis B virus, and hepatitis C
virus were prepared from fresh buffy coats obtained from
Etablissement de Transfusion Sanguine (Paris). Centrif-
ugation on Ficoll-Hypaque gradients was routinely used
to isolate PBMCs. Freshly isolated cells were suspended
in RPMI medium containing 10% heat-inactivated FBS
and used in experiments on the same day.
Antisera, monoclonal antibodies, and recombinant
glycoproteins
Patient-derived neutralizing anti-HSV-1 sera had anti-
HSV-1 titers of 3000–4000 IU/ml by ELISA (assay kit
supplied by Behringwerke, Marburg, Germany). These
sera were decomplemented before use. A rabbit anti-
HSV-1 antiserum and the non-neutralizing mouse mAbs
reactive with HSV-1- and -2-derived glycoproteins gB, gC,
gD, and gE were kindly furnished by Dr. Stig Jeansson
(Oslo, Norway) (H2G4B1, B1C1B4, E5G3G9, and B1E6A5;
Bergstroem et al., 1992; Trybala et al., 1993). Neutralizing
mouse mAbs recognizing HSV-1- and -2-derived gD were
donated by Dr. Tony Minson (Cambridge, UK) (LP2; Min-
son et al., 1986) and Dr. Martin Zweig (Frederick, MD)
(4S; Showalter et al., 1981). The polyclonal rabbit anti-
gH/gL serum (R 137) recognizing the native gH–gL com-
plex was a kind gift of Drs. Gary Cohen and Roselyn
Eisenberg (Philadelphia, PA) (Peng et al., 1998). A gG-
specific mouse mAb was obtained from Advanced Bio-
technologies (Columbia, MD). An IFN-a-specific neutral-
izing sheep polyclonal antibody was prepared at Unite´
43, INSERM (Paris, France). The mouse mAb GalC was
from Boehringer-Mannheim (Mannheim, Germany). This
antibody binds galactocerebrosides and psychosine
equally well and cross-reacts with sulfatides with a 16-
fold lower titer (Rantscht et al., 1982). The mAbs to the
chemokine receptors CXCR4 (12G5) and CCR3 (7B11)
were provided by the NIH Aids Research and Reference
Reagent Program (Rockville, MD) and by the MRC Aids
Reagent Project (Potters Bar, UK). Anti-CXCR4 receptor
had been made available by Dr. James Hoxie (Philadel-
phia, PA), and anti-CCR3 receptor had been made avail-
able by LeukoSite (Cambridge, MA) (Endres et al., 1996;
Heath et al., 1997; Wu et al., 1997). The 12G5 hybridoma
line was made available by Dr. Marc Alizon (Paris). A
mouse hybridoma line expressing mAb ACN5 to the
baculovirus glycoprotein gp67 was a gift from Dr. Peter
Faulkner (Kingston, Ontario, Canada) (Whitford et al.,
1989). Hybridoma culture supernatants were used di-
rectly for immunofluorescence studies of baculovirus-
infected Sf9 cells. The soluble recombinant gHt–gL com-
plex contains the extramembranous domain of gH (res-
idues 1–719, including the signal sequence) elongated
by a hexahistidinyl tail at the carboxyl end and full-length
mature gL [gH-1t(His)6/gL-1]. It was purified by metal
chelate affinity chromatography from culture superna-
tants of Sf9 cell cultures infected with a baculovirus
construct expressing both glycoproteins (Westra et al.,
1997; Westra and Welling-Wester, in preparation). The
recombinant extramembranous portion of glycoprotein
gD was isolated from culture supernatants of Sf9 cells
infected with a baculovirus construct expressing the N-
terminal 315 amino acids of the complete mature
polypeptide of HSV-1 (gD-1t; Damhof, 1995; Westra and
Welling-Wester, unpublished results).
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IFN induction and assay
Freshly isolated PBMCs (6 3 106/ml) were incubated
at 37°C for ;18 h in 0.1 ml of RPMI–10% FBS with added
HSV-1 or control virus, inducer Sf9 cells, or glycoprotein
at indicated concentrations. At the end of the reaction, 5
ml of 1 N HCl was added to inactivate live virus where
applicable. Supernatants were removed and serially di-
luted 2-fold in duplicate. MDBK cells in MEM–10% FBS
were added, and mixtures were incubated for an addi-
tional 24 h at 37°C, followed by infection with VSV.
Cytopathic effects were scored under the microscope
24 h later. Titration end points represent dilutions that
gave destruction of 50% of the cells. A laboratory refer-
ence of human IFN-a, which had been standardized with
the NIH Ga 023–902-530 reference, was included with
each titration. Duplicates usually varied by no more than
one dilution. One international unit of IFN activity (IU)
represents the reciprocal of the dilution that results in
50% of cell destruction, corrected for the value obtained
with the IFN-a standard. Although MDBK cells are of
bovine origin, they are as sensitive to human IFN-a as
human fibroblasts. They do not respond to human IFN-g
and poorly to human IFN-b, and thus define human
cell-derived antiviral activity as IFN-a (Gresser et al.,
1974). In addition, antiviral activies induced by Sf9-gD
and recombinant glycoprotein gDt were further charac-
terized by neutralization with IFN-a-specific antiserum.
Immunofluorescence and inhibition studies
For immunofluorescence, PBS-washed Sf9 cells ex-
pressing HSV glycoproteins were fixed onto slides with
acetone, and then primary antibodies were added for 30
min at 37°C. After washing with PBS, slides were devel-
oped with appropriate fluorescein-conjugated anti-IgG
second antibody. To visualize surface-expressed viral
glycoproteins, washed cells were suspended in PBS
containing sera or mAbs at 4°C for 1 h, washed again,
and further processed with the appropriate fluoresceine-
labeled anti-IgG second antibody. In the inhibition stud-
ies using antisera or mAbs against gD, both inducer and
mAb were mixed and preincubated for 15 min at 37°C
before PBMCs were added, and incubation was contin-
ued overnight. In the studies with antisera or mAbs that
recognize cell surface components, PBMC and antibod-
ies were preincubated for 15 min at 37°C before induc-
ers were added.
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